Why did Medline lower its full-year 2026 adjusted EBITDA guidance despite reporting 12% sales growth in Q2 2026?
What happened to the guidance Medline trimmed its full year 2026 adjusted EBITDA target from $3.5 billion $3.6 billion down to $3.3 billion $3.4 billion 1 8 23 . The cut came in the same report that showed second quarter net sales up about 12% year over year to roughly...
0000